William Conkling
Chief Executive Officer at RAFAEL HOLDINGS, INC.
Net worth: 934 171 $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Charles Strattan | M | 78 | 34 years | |
| Jeffrey Tate | M | 66 | 14 years | |
| Robert G. L. Shorr | M | 71 |
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Joshua David Rubin | M | - |
Day Three Labs, Inc.
 Day Three Labs, Inc. Information Technology ServicesTechnology Services Day Three Labs, Inc. is a cannabinoid CPG ingredient manufacturer that specializes in developing and commercializing novel cannabis product solutions. The company is based in Denver, CO, and has research operations in Israel. Day Three Labs taps into over 50 years of scientific research and plant study to reimagine existing cannabis offerings by delivering innovation and ingenuity to the cannabis industry. The company's portfolio includes proprietary pharmaceutical-grade infusion technologies with the objective of handing control of the cannabis experience to the everyday consumer. The company was founded by Rafi Cohen and Joshua David Rubin, and Joshua David Rubin has been the CEO since incorporation. | 7 years |
| Sanjeev Luther | M | 62 |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | 9 years |
| Scott Fine | M | 67 | 10 years | |
| Howard Jonas | M | 68 |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | 11 years |
| Markus Walter Sieger | M | 58 | 10 years | |
| Andrew Dickinson | M | 54 | 4 years | |
| Rafi Cohen | M | - |
Day Three Labs, Inc.
Day Three Labs, Inc. Information Technology ServicesTechnology Services Day Three Labs, Inc. is a cannabinoid CPG ingredient manufacturer that specializes in developing and commercializing novel cannabis product solutions. The company is based in Denver, CO, and has research operations in Israel. Day Three Labs taps into over 50 years of scientific research and plant study to reimagine existing cannabis offerings by delivering innovation and ingenuity to the cannabis industry. The company's portfolio includes proprietary pharmaceutical-grade infusion technologies with the objective of handing control of the cannabis experience to the everyday consumer. The company was founded by Rafi Cohen and Joshua David Rubin, and Joshua David Rubin has been the CEO since incorporation. | 9 years |
| Joshua Fine | M | 42 | 10 years | |
| Randall Toig | M | 73 | 6 years | |
| Christina Carlson | F | - | 4 years | |
| Stephen Greenberg | M | 80 | 6 years | |
| F. Ostronic | M | 68 | 10 years | |
| William Shanahan | M | 84 | 8 years | |
| Brett Pletcher | M | 56 | 4 years | |
| David Polinsky | M | 53 | 7 years | |
| Mark McCamish | M | 72 | 3 years | |
| Michael Weiss | M | 73 | 6 years | |
| Vivien Wong | M | 67 | 1 years | |
| Tiby Erdely | M | - |
Day Three Labs, Inc.
Day Three Labs, Inc. Information Technology ServicesTechnology Services Day Three Labs, Inc. is a cannabinoid CPG ingredient manufacturer that specializes in developing and commercializing novel cannabis product solutions. The company is based in Denver, CO, and has research operations in Israel. Day Three Labs taps into over 50 years of scientific research and plant study to reimagine existing cannabis offerings by delivering innovation and ingenuity to the cannabis industry. The company's portfolio includes proprietary pharmaceutical-grade infusion technologies with the objective of handing control of the cannabis experience to the everyday consumer. The company was founded by Rafi Cohen and Joshua David Rubin, and Joshua David Rubin has been the CEO since incorporation. | 3 years |
| Craig Moskowitz | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Eric Cutsem | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Gus Kodersha | M | - | 3 years | |
| Susan Bernstein | F | 59 | - | |
| John Goldberg | M | 51 | 1 years | |
| Aaron Drillick | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Michael Lisjak | M | 50 | 5 years | |
| Chi Van Dang | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Rangarajan Sundaram | M | 62 |
The Leonard N Stern School of Business
| 28 years |
| A Joseph Stern | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Patrick Wilmerding | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Joyce Mason | F | 65 | 7 years | |
| Shawn Cross | M | 56 | 1 years | |
| Zuzana Zachar | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Paul Bingham | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | - |
| Barbara Ryan | F | 64 | - | |
| Shmuel Levinger | M | - |
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Menachem Ash | M | 52 | 4 years | |
| Harout Semerjian | M | 52 | - | |
| Michael Pehl | M | 60 | 2 years | |
| Michael R. Garone | M | 66 | 3 years | |
| Patrick Fabbio | M | 56 | 2 years | |
| Scott Canute | M | 63 | 3 years | |
| Chau Cheng | M | - | 16 years | |
| Nick Markola | M | - |
The Leonard N Stern School of Business
| 3 years |
| Jared M. Freedberg | M | 55 | 2 years | |
| Boris Pasche | M | 63 | 5 years | |
| Ameet Mallik | M | 51 | 1 years | |
| Charles Baum | M | 65 | 1 years | |
| Usama Malik | M | 49 | 3 years | |
| Thomas Lee | M | - |
The Leonard N Stern School of Business
| 8 years |
| Glenn Perillo | M | - |
The Leonard N Stern School of Business
| 5 years |
| Shannon Klinger | M | 53 | 1 years | |
| Behzad Aghazadeh | M | 52 | 3 years | |
| Mallory Morales | F | 40 | 2 years | |
| Khalid Islam | M | 67 | 3 years | |
| Peter Hutt | M | 89 | 3 years | |
| Barbara Duncan | F | 59 | 1 years | |
| Vadim Komissarov | M | 52 |
The Leonard N Stern School of Business
| 2 years |
| Zachary L. Venegas | M | 53 |
The Leonard N Stern School of Business
| 2 years |
| Jim Rowley | M | - |
The Leonard N Stern School of Business
| 2 years |
| David Perkal | M | - |
The Leonard N Stern School of Business
| 2 years |
| Nicolo Antonio Celentano | M | - |
The Leonard N Stern School of Business
| 2 years |
| Michael Aingorn | M | - |
The Leonard N Stern School of Business
| 4 years |
| Amit Sinha | M | - |
The Leonard N Stern School of Business
| 2 years |
| Don Charlton | M | - |
The Leonard N Stern School of Business
| 2 years |
| Ahmad Deek | M | 57 |
The Leonard N Stern School of Business
| 2 years |
| Keith Anthony Dubauskas | M | - |
The Leonard N Stern School of Business
| 5 years |
| Jeffrey Bernstein | M | - |
The Leonard N Stern School of Business
| 2 years |
| Karina Kirk | F | 53 |
The Leonard N Stern School of Business
| 1 years |
| Thomas Gray | M | - |
The Leonard N Stern School of Business
| 2 years |
| Sean Fang | M | 54 |
The Leonard N Stern School of Business
| 2 years |
| Eric Ende | M | 55 |
The Leonard N Stern School of Business
| 2 years |
| Wen Jun Sun | M | 58 |
The Leonard N Stern School of Business
| 2 years |
| John Eidinger | M | 43 |
The Leonard N Stern School of Business
| 4 years |
| Matthew Goodman | M | 49 |
The Leonard N Stern School of Business
| 2 years |
| David Leong | M | - |
The Leonard N Stern School of Business
| 4 years |
| Ari Dean Sass | M | - |
The Leonard N Stern School of Business
| 3 years |
| Matthew Konosky | M | - |
The Leonard N Stern School of Business
| 2 years |
| Marco Maria Bianconi | M | 58 |
The Leonard N Stern School of Business
| 2 years |
| Robby Abraham | M | - |
The Leonard N Stern School of Business
| 4 years |
| Humberto Zesati | M | 57 |
The Leonard N Stern School of Business
| 2 years |
| Bill Lee | M | - |
The Leonard N Stern School of Business
| 2 years |
| Henry Shields Day | M | - |
The Leonard N Stern School of Business
| 3 years |
| Thomas Deierlein | M | - |
The Leonard N Stern School of Business
| 2 years |
| Matthew Kimble | M | - |
The Leonard N Stern School of Business
| 2 years |
| Gao Bin | M | 61 |
The Leonard N Stern School of Business
| 3 years |
| Matt Jenkin | M | - |
The Leonard N Stern School of Business
| 2 years |
| Jason Wolin | M | - |
The Leonard N Stern School of Business
| 4 years |
| Diane Wiedinger Keady | F | 54 |
The Leonard N Stern School of Business
| 4 years |
| David Goodman | M | - |
The Leonard N Stern School of Business
| 4 years |
| Jay Patel | M | - |
The Leonard N Stern School of Business
| 4 years |
| Scott T. Lowry | M | 57 |
The Leonard N Stern School of Business
| 4 years |
| Joel Krikston | M | - |
The Leonard N Stern School of Business
| 2 years |
| Craig Lawrence Armstrong | M | - |
The Leonard N Stern School of Business
| 3 years |
| Rob Hinchliffe | M | - |
The Leonard N Stern School of Business
| 3 years |
| Peter Albanese | M | - |
The Leonard N Stern School of Business
| 3 years |
| Yulia Germanovna Chupina | F | 53 |
The Leonard N Stern School of Business
| - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- William Conkling
- Personal Network
